Search Results for "Contraceptives"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Contraceptives. Results 41 to 50 of 121 total matches.
Cemiplimab (Libtayo) for NSCLC (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
harm and death.
Women of reproductive potential should use effective
contraception during treatment ...
The FDA has approved cemiplimab-rwlc (Libtayo –
Regeneron), an immune checkpoint inhibitor, for use in
combination with platinum-based chemotherapy for
first-line treatment of locally advanced or metastatic
non-small cell lung cancer (NSCLC) in adults with no
epidermal growth factor receptor (EGFR), anaplastic
lymphoma kinase (ALK), or ROS1 aberrations and
who are not candidates for surgical resection or
chemoradiation. The drug was previously approved
for first-line treatment of NSCLC in patients whose
tumors have high PD-L1 expression and no genomic
tumor aberrations....
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e67-8 doi:10.58347/tml.2023.1674e | Show Introduction Hide Introduction
Futibatinib (Lytgobi) for Cholangiocarcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
studies.
Women of reproductive potential and their male
partners should use effective contraception ...
The oral kinase inhibitor futibatinib (Lytgobi –
Taiho) has received accelerated approval from the
FDA for treatment of adults with previously treated,
unresectable, locally advanced or metastatic
intrahepatic cholangiocarcinoma with fibroblast
growth factor receptor 2 (FGFR2) fusions or other
rearrangements. Accelerated approval was based
on the overall response rate and duration of
response. Futibatinib is the second drug to be
approved for this indication; pemigatinib (Pemazyre)
was approved earlier.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e69-70 doi:10.58347/tml.2023.1674f | Show Introduction Hide Introduction
In Brief: A New Indication for Pemigatinib (Pemazyre) (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
should use effective contraception
during treatment with pemigatinib and for 1 week
after the last dose ...
The oral kinase inhibitor pemigatinib (Pemazyre –
Incyte) has been approved by the FDA for treatment
of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth
factor receptor 1 (FGFR1) rearrangements. It is the
first targeted therapy to be approved in the US for this
indication. The drug received accelerated approval
from the FDA in 2020 for treatment of adults with
previously treated, unresectable, locally advanced or
metastatic cholangiocarcinoma with FGFR2 fusions
or other rearrangements.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e71-2 doi:10.58347/tml.2023.1674g | Show Introduction Hide Introduction
In Brief: Retifanlimab (Zynyz) for Merkel Cell Carcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
.
Women of reproductive potential should use effective
contraception during treatment with retifanlimab ...
Retifanlimab-dlwr (Zynyz – Incyte), a programmed
death receptor-1 (PD-1) blocking antibody, has
received accelerated approval from the FDA for
treatment of metastatic or recurrent locally advanced
Merkel cell carcinoma (MCC) in adults. Accelerated
approval of the drug was based on the response rate
and duration of response. Retifanlimab is the third
drug to be approved in the US for treatment of MCC;
pembrolizumab (Keytruda), a PD-1 blocking antibody,
is approved for the same indication as retifanlimab
in patients ≥12 years old and avelumab (Bavencio),
a programmed death...
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e73-4 doi:10.58347/tml.2023.1674h | Show Introduction Hide Introduction
In Brief: Dabrafenib (Tafinlar) and Trametinib (Mekinist) for Glioma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
concentrations of many
drugs, including midazolam, warfarin, dexamethasone,
and hormonal contraceptives ...
The oral kinase inhibitors dabrafenib (Tafinlar –
GSK) and trametinib (Mekinist – Novartis) have been
approved by the FDA for use together for a sixth
indication: treatment of low-grade glioma (LGG)
with a BRAF V600E mutation in patients ≥1 years old
who require systemic therapy. This combination is
the first systemic therapy to be approved in the US
for first-line treatment of LGG with a BRAF V600E
mutation in pediatric patients. The FDA also approved
new oral formulations of both drugs for patients
who are unable to swallow dabrafenib capsules or
trametinib...
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e75-6 doi:10.58347/tml.2023.1674i | Show Introduction Hide Introduction
Three Drugs for Atopic Dermatitis (Adbry, Cibinqo, and Rinvoq)
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
contraception while
taking upadacitinib and for 4 weeks after stopping
the drug. Upadacitinib ...
The subcutaneously injected interleukin-13 (IL-13)
antagonist tralokinumab-ldrm (Adbry – Leo) and
the oral Janus kinase (JAK) inhibitors abrocitinib
(Cibinqo – Pfizer) and upadacitinib (Rinvoq – Abbvie)
have been approved by the FDA for treatment of
moderate to severe atopic dermatitis.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):51-5 doi:10.58347/tml.2023.1673b | Show Introduction Hide Introduction
Atezolizumab (Tecentriq) for Alveolar Soft Part Sarcoma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
fetal harm and death.
Women of reproductive potential should use effective
contraception during ...
Atezolizumab (Tecentriq – Genentech), an immune
checkpoint inhibitor, has been approved by the FDA
for treatment of unresectable or metastatic alveolar
soft part sarcoma (ASPS) in patients ≥2 years old. It
was previously approved for treatment of non-small
cell lung cancer, small cell lung cancer, hepatocellular
cancer, and melanoma (see Table 1). Atezolizumab is
the first drug to be approved in the US for treatment
of ASPS. ASPS is a rare disorder that affects mostly
adolescents and young adults; <1% of soft tissue
sarcomas are ASPS.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):e56-7 doi:10.58347/tml.2023.1673d | Show Introduction Hide Introduction
Dostarlimab (Jemperli) for Endometrial Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
use effective
contraception during treatment with dostarlimab and
for 4 months after the last dose ...
The FDA has granted regular approval to dostarlimabgxly
(Jemperli – GSK), an immune checkpoint
inhibitor, for treatment of adults with mismatch repair
deficient (dMMR) recurrent or advanced endometrial
cancer that has progressed on or following a prior
platinum-containing regimen in any setting and who
are not candidates for curative surgery or radiation.
Dostarlimab received accelerated approval in 2021
for treatment of adults with dMMR recurrent or
advanced endometrial cancer or nonendometrial
solid tumors that progressed on or following prior
treatment and who have no...
Med Lett Drugs Ther. 2023 Apr 3;65(1673):e64-5 doi:10.58347/tml.2023.1673h | Show Introduction Hide Introduction
Ublituximab (Briumvi) for Relapsing Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Mar 06, 2023 (Issue 1671)
contraception while receiving
ublituximab and for 6 months after stopping it. Live
vaccines should ...
The FDA has approved the recombinant chimeric
anti-CD20 antibody ublituximab-xiiy (Briumvi – TG Therapeutics) for IV treatment of adults with
relapsing forms of multiple sclerosis (MS), including
clinically isolated syndrome (initial neurological
episode), relapsing-remitting disease, and active
secondary progressive MS (SPMS). Two other anti-CD20 antibodies, IV ocrelizumab (Ocrevus) and SC
ofatumumab (Kesimpta), are also FDA-approved for
these indications.
Med Lett Drugs Ther. 2023 Mar 6;65(1671):36-8 doi:10.58347/tml.2023.1671c | Show Introduction Hide Introduction
In Brief: Adstiladrin – A Gene Therapy for Bladder Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Mar 06, 2023 (Issue 1671)
contraception during
treatment and for 6 months (females) or 3 months
(males) after the last dose. No data ...
Nadofaragene firadenovec-vncg (Adstiladrin – Ferring), an adenoviral vector-based gene therapy,
has been approved by the FDA for treatment of adults
with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer
(NMIBC) with carcinoma in situ with or without
papillary tumors. It is the first adenoviral vector-based
gene therapy to be approved in the US for
this indication. The immune checkpoint inhibitor
pembrolizumab (Keytruda) was approved for the
same indication in 2021.
Med Lett Drugs Ther. 2023 Mar 6;65(1671):e40-1 doi:10.58347/tml.2023.1671e | Show Introduction Hide Introduction